Interferon regulatory factor-1 (IRF-1) is a nuclear transcription factor that mediates interferon and other cytokine effects and appears to have antitumor activity in vitro and in vivo in cancer cells. We have constructed a recombinant adenoviral vector (Ad-IRF-1) that infects mammary cells with high efficiency and results in high levels of functional IRF-1 protein in transfected cells. Overexpression of IRF-1 in two mouse breast cancer cell lines, C3-L5 and TS/A, resulted in apoptosis in these cell lines as assessed by Annexin V staining. The involvement of caspases was confirmed by significant inhibition of apoptosis by a caspase inhibitor, and by demonstration of caspase-3 activity, cleavage of caspase-3, and PARP cleavage. Interestingly, the growth of nonmalignant breast cell lines C127I and NMuMG did not appear to be inhibited by IRF-1 overexpression. Suppression of growth for breast cancer cell lines in vivo was demonstrated by both preinfection of breast cancer cells ex vivo and by intratumoral injection of Ad-IRF-1 into established tumors in their natural hosts. The mechanism of apoptosis may involve the transcriptional upregulation of bak, caspase-8, and caspase-7 expression. These data support the antitumor potential of IRF-1 and the use of agents that increase IRF-1 in breast cancer.
Introduction
Interferons, cytokines, retinoids, and antiestrogen agents induce the expression of the trancription factor interferon regulatory factor-1 (IRF-1) (Skaar et al., 1998; Bouker et al., 2002; Taniguchi et al., 2001) . Interferons bind to complex receptors that activate JAK-STAT signal transduction proteins (Ihle, 1996) . STAT1 homodimers translocate from the cytoplasm into the nucleus and bind to an enhancer element in the promoter of IRF-1 that activates its transcription and translation (Kroger et al., 2002) . As a nuclear transcription factor itself, IRF-1 then binds to specific DNA sequences in several promoters to initiate the transcription of specific genes involved in numerous physiological processes Harada et al., 1989) . These genes include the upregulation of interferons a and b, as well as major histocompatibility complex (MHC) class I and II expression (Chang et al., 1992; Yim et al., 1997) . In macrophages, IRF-1 also increases the expression of inducible nitric oxide synthase (iNOS), the inducible isoform of the enzyme that produces nitric oxide (Spink and Evans, 1997) . Interestingly, IRF-1 can also decrease the expression of tumor-promoting genes, including hTERT (Lee et al., 2003) .
We and others have demonstrated enhanced immunogenicity and tumor suppressor activity of IRF-1 in vitro and in vivo (Yim et al., 1997; Kroger et al., 2001 Kroger et al., , 2003 . Liposomal transfection of plasmid vector with stable expression of IRF-1 in nonimmunogenic mouse MCA101 sarcoma cells resulted in increased expression of MHC I and II (Yim et al., 1997) . IRF-1 expression also suppressed cell proliferation and anchorage-independent growth, and slowed the growth of highly expressing clones in vivo. Another model was used to examine the effects of IRF-1 expression on hepatocellular carcinoma by testing clones transfected with an inducible IRF-1 expression vector. That study demonstrated significant antitumoral immune responses and immunity against a fetoprotein, a tissue-specific selftumor antigen (Kroger et al., 2001) .
The magnitude of breast cancer as a health problem has warranted the search for innovative therapies (Baselga and Norton, 2002; Jemal et al., 2002) . Many tumors are resistant to the induction of apoptosis by chemotherapy, radiation, and other cytokines (Reed, 1999) . IRF-1 has been linked to cancer based on comparative genomic hybridization (Nishizaki et al., 1997; Tirkkonen et al., 1998) and loss of heterozygosity in several tumor types (Kashiwaba et al., 1994; O'Connell et al., 1998; Paulson et al., 1999) . There have been few studies demonstrating the role of IRF-1 specifically in the pathology and treatment of breast cancer. One study demonstrated a loss of IRF-1 expression in a significant proportion of breast cancers supporting a role for IRF-1 as a tumor suppressor gene (Doherty et al., 2001) .
Despite the potential efficacy of IRF-1 expression to limit tumor growth, the previous studies demonstrating an antitumor effect from IRF-1 expression have limited therapeutic value because liposomal transfection has poor efficacy of gene transfer that requires the isolation of clones with high IRF-1 or inducible IRF-1 expression. The expression of IRF-1 has been found to result in apoptosis in certain cell systems (Nguyen et al., 1997; Kirchhoff and Hauser, 1999) , but study of this phenomenon has been hampered by the cytotoxic or growth inhibitory nature of IRF-1. Inducible systems have been developed (Sanceau et al., 2000; Kroger et al., 2001) , but these systems can have a relatively high background of expression in the uninduced state , which we believe has prevented successful selection of inducible clones in breast cancer cell lines (unpublished data). This also limits the ability to obtain meaningful results from in vivo experiments. Therefore, we constructed a replication-deficient adenoviral vector that can infect cancer cells with high efficiency of gene transfer to overexpress IRF-1 (Ad-IRF-1). We hypothesized that overexpression of IRF-1 in breast cancer cells would induce tumor suppression in vitro and in vivo. The focus of this study was to examine the role of apoptosis induced by IRF-1 in tumor growth inhibition. We examined the potential mechanism for IRF-1-induced apoptosis by measuring caspase-3 activity and PARP cleavage, and we screened by microarray analysis to define potential proapoptotic genes that are upregulated and activated by IRF-1 in breast cancer.
Results

Construction of Ad-IRF-1 and functional expression of IRF-1
To assess fully the capacity of IRF-1 to limit breast cancer cell growth, we constructed a recombinant adenovirus containing the mouse IRF-1 gene under a constitutive, cytomegalovirus promoter (Ad-IRF-1). This construct allows for high efficiency gene transfer and study of treated cells in real time. We first confirmed high efficiency of adenoviral gene transfer in breast cell lines using a recombinant adenovirus expressing the enhanced green fluorescent protein (Ad-EGFP), which is readily identified under fluorescent microscopy and flow cytometry. Cells infected with Ad-EGFP displayed greater than 95% infectivity at a multiplicity of infection (MOI) of 200 in TS/A and C3-L5 mouse breast cancer cells as well as the nonmalignant mammary cell line C127I (data not shown). The nonmalignant breast cell line NMuMG displayed greater than 95% infectivity at a lower MOI of 10 (data not shown).
Western blotting demonstrated that Ad-EGFP infection resulted in minimal expression of endogenous IRF-1 protein in C3-L5 and TS/A cells (Figure 1a ). High expression of IRF-1 protein was observed by immunoblotting at 24 h in both TS/A and C3-L5 cell lines with less IRF-1 expression at 48 h ( Figure 1a) . The nonmalignant breast cell line NMuMG also showed high expression of IRF-1 at lower MOIs by 24 h after infection with Ad-IRF-1 (Figure 1b) . Upregulation of MHC class I expression is the most well-known function of IRF-1 (Chang et al., 1992) . To confirm that the IRF-1 protein expressed in these cell lines was functional, we measured the expression of MHC class I proteins in both C3-L5 and TS/A cells. Ad-EGFP produces a markedly fluorescent protein that results in spectrophotometric activity in not only the green spectrum but also in other wavelengths as well. Owing to this and concerns for interference in other colorimetric and fluorometric assays we used the empty vector Ad-C5 as the control for the rest of the experiments. Ad-C5 demonstrates no upregulation of IRF-1 at any MOI or at any time point in every cell line by Western blot (data not shown). As seen in Figure 1d , Ad-IRF-1 infection resulted in a markedly increased expression of haplotype-specific MHC class I proteins in the two mouse breast cancer cell lines C3-L5 and TS/A as assessed by flow cytometry. There was no difference in MHC class I expression between mock-infected cells (no virus) and empty vector control (Ad-C5)-infected cells. However, C3-L5 cells infected with Ad-IRF-1 demonstrated markedly increased levels of cell-surface MHC I protein H-2 K k and significantly increased levels of two MHC class I proteins (H2-K d and H2-D d ) on the cell surface of TS/A cells (Figure 1d ). TS/A already had significant levels of MHC class I expression on the cell surface at baseline, but Ad-IRF-1 significantly increased both MHC class I proteins, while Ad-C5 did not change MHC class I expression compared to mock infection (mean channel fluorescence of (Ad-C5 versus mock) 8.58 versus 9. 16, 54.33 versus 53.20, and 126.22 Another well-known function of IRF-1 is the transcriptional upregulation of IFN-a (Harada et al., 1990) . As seen in Figure 1c , IFN-a was increased more than 30-fold in the supernatants of C3-L5 and NMuMG cells by Ad-IRF-1 with no appreciable levels of IFN-a in mock-or Ad-C5-infected controls. Interestingly, while TS/A did show significantly increased levels of IFN-a; it was not to nearly the same degree as in supernatants of C3-L5 and NMuMG cells.
IRF-1 induces apoptosis and growth arrest in breast cancer cells, but not in nonmalignant cells
Programmed cell death, or apoptosis, can be induced by multiple cell signaling mechanisms (Green and Evan, 2002) , and IRF-1 has been previously reported to induce apoptosis in other cell types (Tanaka et al., 1994a; Tamura et al., 1995; Nguyen et al., 1997; Kano et al., 1999a; Kirchhoff and Hauser, 1999) , but not in breast cancer cells. The high efficiency of IRF-1 gene transfer by Ad-IRF-1 allowed us to examine the entire population of breast cancer cells for apoptosis. Treatment of cells with no virus or Ad-C5 did not affect the appearance of C3-L5 cells grown in culture (Figure 2a) . However, Ad-IRF-1 infection of C3-L5 cells resulted in a decrease in the number of bright, round, mitotic cells, loss of adherent cells, and an increase in cells with cytoplasmic blebbing and condensed cytoplasm consis-tent with the morphology of apoptosis induced by IRF-1 expression. Annexin V binding to cell-surface phosphatidyl serine is one hallmark of apoptotic cell death (Koopman et al., 1994) , and propidium iodide (PI), which stains DNA, is a marker for permeabilized, necrotic cells. Compared to mock or Ad-C5 infection, both C3-L5 and TS/A cell lines displayed a profound increase in Annexin V-positive as well as PI-positive cells after infection with Ad-IRF-1 (Figure 2b ). C3-L5 displayed a higher apoptotic and necrotic fraction than TS/A cells. Time course studies of Annexin V-and PIpositive cells are consistent with progression to necrosis from apoptosis as the ratio of apoptotic fraction to necrotic fraction was higher in earlier time points (data not shown). TS/A cells at 24 h did demonstrate marginally increased apoptotic and necrotic fraction (data not shown) that was clearly more evident at 48 h.
Most apoptotic cell death pathways involve caspase proteases, a family of aspartyl proteases that mediate intracellular apoptotic signaling (Thornberry and Lazebnik, 1998) . Incubation of C3-L5 and TS/A cells with the pan-caspase inhibitor Z-VAD-fmk partially decreased both apoptotic and necrotic fractions in Ad-IRF-1-infected cells (Figure 2b ). Z-VAD-fmk had no effect or marginally increased or decreased the apoptotic or necrotic fraction in mock-or Ad-C5-infected cells (data not shown). This suggested that IRF-1 expression induced cell death in breast cancer cells by mechanisms that are in part mediated by caspases.
To confirm further that IRF-1 expression resulted in cell death by an apoptotic mechanism via caspases, we assayed for caspase-3 enzymatic activity, caspase-3 cleavage, as well as PARP cleavage. First, we demonstrated that infection of C3-L5 cells with Ad-IRF-1 at MOI 200 resulted in the expression of IRF-1 by 6 h after infection (Figure 3a) . Ad-IRF-1 infection resulted in significantly higher caspase-3 activity levels at 12 h (P ¼ 0.008 versus Mock, P ¼ 0.02 versus Ad-C5 by two-tail t-test), and even higher caspase-3 activity levels by 18 and 24 h after infection compared to C3-L5 cells infected with mock or control Ad-C5 (Figure 3b ). These (Figure 3c ). A slight decrease in the levels of inactive, procaspase-3 was observed at 18 and 24 h after Ad-IRF-1 infection. Activated caspase-3 or PARP cleavage was not significantly detected in C3-L5 cells infected with Ad-C5 or media alone (mock) as controls.
IRF-1 transfection was shown previously to decrease cell proliferation in melanoma and sarcoma cells (Yim et al., 1997 (Yim et al., , 1999 . Since fewer mitotic cells were observed after Ad-IRF-1 infection (Figure 2a) , we assessed for cell growth after Ad-IRF-1 infection using an MTT assay that is known to stain cells with active respiratory capacity. The MOI needed for 495% transfection efficiency as assessed by the number of green cells from Ad-EGFP infection were similar for TS/A, C3-L5, and C127I, but NMuMG required only 10 MOI for 495% green cells so we therefore chose an MOI of Ad-C5 well over twice that needed for evaluation of this nonmalignant breast cell line. Compared to control infection with Ad-C5, IRF-1 expression was found to decrease cell growth in both C3-L5 and TS/A cells, but not in C127I or NMuMG cells (Figure 3d ). Consistently, C3-L5 cells were more sensitive to the induction of cell death by Ad-IRF-1 than TS/A cells.
IRF-1 expression induces cell death in mammary tumors in vivo
The inhibition of cell growth as well as induction of apoptotic cell death by IRF-1 expression in C3-L5 and TS/A cells supported our hypothesis that IRF-1 expression could be used to prevent tumor growth of breast cancers. In addition, the paucity of the effects of Ad-IRF-1 on cell death and proliferation that was observed in nontransformed cells suggested that IRF-1 expression might be useful to target breast cancer cells in animals without toxicity to the host. C3-L5 and TS/A cells can be grown as tumors in syngeneic C3H/HeJ and BALB/c mice, respectively. Mice were injected with cancer cells transduced ex vivo to evaluate tumor responses under optimal conditions of gene transfer. In C3-L5 cells, ex vivo infection with Ad-IRF-1 (MOI 200) completely prevented tumor formation in syngeneic C3H/HeJ mice in four out of five mice treated. Tumor-free survival was significantly different compared to both Ad-C5 treatment (n ¼ 5) and mock treatment (n ¼ 10) in which 100% of mice developed measurable tumors (Table 1; Fisher's exact two-sided t-test; Po0.05). Of mice with C3-L5 breast tumors that were injected with Ad-IRF-1, only one displayed any measurable signs of tumor at day 60, whereas all Ad-C5-or mock-infected mice had large tumors. For TS/A cells, cells were treated ex vivo with empty vector control virus Ad-C5 or Ad-IRF-1 (MOI 200) or mock infected and then injected subcutaneously (5 Â 10 5 cells/mouse) into the mammary line of BALB/c syngeneic mice. Ad-C5 virus did not affect tumor growth compared to mock-infected controls. Ex vivo treatment of TS/A cells with Ad-IRF-1 (MOI 200) did not prevent TS/A tumor formation, but did result in prolonged tumor latency and markedly slowed tumor growth after in vivo implantation (Figure 4a ).
We then tested whether repeated, intratumoral Ad-IRF-1 injection could affect mammary cancer growth in vivo. Three, subcutaneous intratumoral injections of Ad-IRF-1 (2 Â 10 8 plaque-forming units (PFU)) resulted in the inhibition of C3-L5 tumor growth in syngeneic C3H/ HeJ mice that was statistically significant by 25 days after tumor cell implantation (Po0.05; Figure 4b ). Likewise, in TS/A tumors grown in syngeneic BALB/c mice, three subcutaneous intratumoral injections of Ad-IRF-1 (2 Â 10 8 PFU) resulted in the inhibition of tumor growth for TS/A tumors (Figure 4c ). This difference Cells were harvested at 24 h for C3-L5 and 48 h for TS/A, and stained with nothing, FITC-Annexin V, PI, or both. The percentage of apoptosis (lower right quadrant) and necrosis (upper right quadrant) is listed at the corresponding quadrant. IRF-1 overexpression (Ad-IRF-1) induces apoptosis (Annexin V ( þ ), PI (À)) and necrosis (Annexin V ( þ ), PI ( þ )) in C3-L5 (24 h) and TS/ A (48 h) breast cancer cells in vitro. Ratios of apoptosis to necrotic cells were higher in earlier time points (data not shown). Apoptosis and necrosis were partially reduced in the presence of 100 mm of Z-VAD-fmk (ZVAD). ZVAD marginally increased or decreased apoptosis and necrosis in control treatments (data not shown) between Ad-IRF-1 and control injections was statistically significant by 30 days after the first injection (Po0.05).
IRF-1 increases expression of proapoptotic genes in breast cancer cells
To examine further the mechanisms by which IRF-1 expression might induce cell death, we assessed for downstream targets of IRF-1 transcriptional regulation that may be involved with the induction of apoptosis. IFN-a has been shown to induce growth arrest in tumor cells (Sangfelt and Strander, 2001 ), and we demonstrated high levels of IFN-a in the supernatant of Ad-IRF-1-infected cells (Figure 1c ), but conditioned media from C3-L5 and TS/A cells infected for 24 h with Ad-IRF-1 did not induce cell death in untreated cell lines (data not shown), and apoptosis was not induced in NMuMG cells by Ad-IRF-1. Therefore, it is unlikely that IFN-a production alone played a significant role in apoptosis induced in C3-L5 or TS/A cells in vitro.
Nitric oxide is a potent inducer of apoptosis in tumor cells (Kim et al., 2001) , and IRF-1 expression by IFN-g is known to induce expression of IRF-1 and iNOS and subsequent nitric oxide synthesis in other cell types (Geller et al., 1993) . Ad-IRF-1 infection of C3-L5 was found to express high levels of iNOS protein by Western blot with significant production of nitrites, the end products of metabolic reactions with newly synthesized nitric oxide, detectable in the culture supernatant (data not shown). However, TS/A cells were not found to demonstrate any detectable iNOS or nitrites (data not shown), even though IRF-1 expression induces cell death in TS/A cells, and once again conditioned media from Ad-IRF-1-infected cells had no effect on growth of either cell line.
The major function of IRF-1 relies on its ability as a transcription factor that potently induces the expression of the mRNA for numerous genes (Taniguchi et al., 2001 ). To determine mechanisms by which IRF-1 expression might induce cell death, we performed a screening microarray analysis on cDNA made from TS/A cells infected at MOI 200 for 24 h with Ad-IRF-1-or Ad-C5-versus mock-infected cells. We found that the expression of IRF-1 increased the expression of four proapoptotic genes versus mock-infected cells not seen with Ad-C5-versus mock-infected cells: caspase-1 (interleukin-1b converting enzyme, accession no. L29095, 9.2-fold), bak (5.7-fold, accession no.Y13231), IRF-1 induces apoptosis in breast cancer cells PKM Kim et al caspase-7 (2.1-fold, accession no. U67321), and caspase-8 (1.5-fold, accession no. AF067835). To confirm this finding, we performed Northern blotting and demonstrated that the expression of bak, a proapoptotic member of the bcl-2 family (Ulrich et al., 1997) , was increased after infection of C3-L5 and TS/A cells with Ad-IRF-1 (Figure 5a ). Caspase-8 is an initiator caspase protease whose activity is thought to result in cleavage and activation of downstream executioner caspases like caspase-3 (Thornberry and Lazebnik, 1998). Northern blotting from C3-L5 and TS/A cells demonstrated an increase in caspase-8 mRNA by 12 h after Ad-IRF-1 infection compared to controls (Figure 5b ). Finally, caspase-7 is considered to be an executioner caspase like caspase-3; Western blotting for caspase-7 clearly demonstrated an increase in procaspase-7 protein expression at B35 kDa by 18-24 h after Ad-IRF-1 infection of C3-L5 and TS/A cells with the corresponding appearance of the classical B20 kDa activated, cleaved caspase-7 fragment, as well as another fragment at B31 kDa (Figure 5c ). There is no question that procaspase-7 is increased in both cell lines at 24 h and later, and the cleavage products are only seen with Ad-IRF-1 in both cell lines versus the controls. The augmentation in the expression of these proapoptotic factors correlated with the activation of caspase-3 and PARP that was observed in Figures 3b and c , and the apoptosis seen in Figure 2b . Caspase-1 and cleavage products were found to be elevated at 24 h in TS/A cells by Western blot, but we were unable to find elevation of caspase-1 in C3-L5 cells despite repeated attempts using the same antibody and a different antibody to perform the Western blot (data not shown). ) were washed and injected in HBSS subcutaneously in the mammary line of 7-9-week-old female Balb/c mice (n ¼ 5 per group). Tumor size was assessed with perpendicular caliper measurements three times per week. (b) Intratumoral Ad-IRF-1 slows tumor growth of the mouse breast cancer cell line TS/ A in vivo in female syngeneic Balb/c mice. TS/A cells were injected at 1 Â 10 5 cells per mouse and tumor growth was assessed. At 12 days mice were randomized to obtain equivalent mean tumor size per group (n ¼ 5) and were then injected intratumorally with 2 Â 10 8 PFU of Ad-C5 or Ad-IRF-1 or saline. Tumor growth was assessed by perpendicular caliper measurements every 2-3 days. Mice received reinjection of Ad-C5, Ad-IRF-1, or saline at the same doses after measurements on days 19 and 26. Tumor sizes were statistically reduced by IRF-1 expression by day 40 (Po0.05 between IRF-1 and either saline or Ad-C5). (c) Intratumoral Ad-IRF-1 slows tumor growth of the mouse breast cancer cell line C3-L5 in vivo in female syngeneic C3H/HeJ mice. C3-L5 cells were injected at 5 Â 10 5 cells per mouse and tumor growth was measured. When tumors were B20 mm 2 , mice were regrouped to obtain equivalent mean tumor size per group (n ¼ 5) and were then injected intratumorally with 2 Â 10 8 PFU of Ad-C5, Ad-IRF-1, or saline. Tumor growth was followed by perpendicular caliper measurements every 2-3 days. Mice received reinjection of Ad-C5, Ad-IRF-1, or saline at the same doses 4 or 9 days after first injection. Tumor sizes were statistically reduced by IRF-1 expression by day 24 (Po0.05 between IRF-1 and either saline or Ad-C5)
-----------------------------------------------------------"
Discussion
We have found that IRF-1 expression potently induces inhibition of growth specifically in tumor cells but not in nonmalignant cell lines in vitro. We have demonstrated that IRF-1 overexpression in C3-L5 and TS/A breast cancer cells induced apoptotic morphology (Figure 2a) with the appearance of several markers characteristic of apoptotic cell death. Ad-IRF-1 infection of C3-L5 cells induced an increase in caspase-3 activity (Figure 3b ), caspase-3 cleavage (Figure 3c ), PARP cleavage (Figure 3c) , and Annexin V staining that was inhibited by a pan-caspase inhibitor (Figure 2b ). IRF-1 clearly increased the expression of three proapoptotic genes in both cell lines: bak, caspase-8, and caspase-7, with activated caspase-7 cleavage products demonstrated ( Figure 5 ). Intratumoral injection of Ad-IRF-1 significantly suppressed tumor growth in both C3-L5 and TS/A animal models of breast cancer. Taken together, these data support the use of gene, molecular, or other therapies of breast cancer by the augmentation of IRF-1 expression to induce tumor cell apoptosis.
The majority of studies demonstrating a role for apoptosis mediated by IRF-1 have been performed with cells that have had the IRF-1 gene deleted. The role of IRF-1 in the induction of apoptosis by DNA damage or IFN-g has been suggested in studies of embryonic fibroblasts from IRF-1 À/À mice transformed by c-Haras (Tanaka et al., 1994a) , IRF-1 À/À mitogen-activated T cells (Tamura et al., 1995) , and IRF-1 À/À hepatocytes (Kano et al., 1999b) . In these models, IRF-1 À/À cells were resistant to apoptosis by DNA damage or IFN-g. Surprisingly, little is known about how IRF-1 induces apoptosis. We have been able to confirm in breast cancer cells one previously postulated mechanism -IRF-1 overexpression does appear to increase caspase-7 protein and cleavage products (Figure 5c ). In one recent study (Tomita et al., 2003) , IRF-1 was found to play a critical role in IFN-g enhancement of fas-mediated apoptosis in renal cell carcinoma cells. IRF-1 antisense ODN treatment inhibited significant increases in caspase-7 mRNA by IFN-g with partial reversal of the enhanced apoptosis. They suggested that caspase-7 may be one of the target genes of IRF-1 and may be a key molecule for inducing apoptosis in these cells. In another study (Sanceau et al., 2000) , IFN-b was found to mediate apoptosis in certain Ewing's sarcoma cell lines, which appeared to be mediated by IRF-1, and involved the activation of caspase-7. Ectopic expression of IRF-1 induced apoptosis in all cell lines, which correlated with the activation of caspase-7. Our data appear to confirm the role of caspase-7 in IRF-1-induced apoptosis in breast cancer cells and once again emphasize the significance of this pathway in IFNmediated apoptosis.
Studies utilizing IRF-1 overexpression have been hindered by the fact that this transcription factor frequently makes it almost impossible to identify and expand stable transfectants due to its suppressive effects on growth (Kirchhoff et al., 1993; Li et al., 1997) . However, there have been several studies using inducible IRF-1 systems that have demonstrated apoptosis. One study used an IRF-1 fusion protein that was activated with estrogen (Kirchhoff and Hauser, 1999) . In NIH3T3 cells, activation of IRF-1 or the oncogene HER1 alone did not result in apoptosis, but when both genes were expressed, the cells were killed by apoptosis. Stat5a was essential for this phenomenon, but signaling intermedi- ates downstream to IRF-1 were not identified. Data not shown from that study did not implicate bak expression as a mechanism for apoptosis; however, we found bak expression to be increased by IRF-1 in both cell lines (Figure 5a ). However, in another study using IFN-g treatment of HT29 cells, IRF-1 appearance was found to correlate with increases in caspase-3 and caspase-7, bak, and CD95 (Ossina et al., 1997) . In a doxycyclineinducible system in NIH3T3 cells, a small amount of apoptosis was found as assessed by acridine orange staining, but a mechanism for this effect was not postulated (Nguyen et al., 1997) . IFN-g increased the expression of caspase-8 in human erythroid progenitor cells which likely utilized IRF-1 signaling and correlates with our findings for this caspase (Figure 5b) .
We also found increases in caspase-1 and caspase-1 cleavage products in the TS/A cell line, confirming the microarray screening of TS/A, but were unable to confirm this in C3-L5 using the same antibody for Western blot as well as another antibody (data not shown). Recently it has been observed that caspase-1 does not frequently act in apoptosis but is rather a cytokine processor (Slee et al., 1999; Wolf and Green, 1999 ). Since we have found more significant apoptosis in C3-L5, but no caspase-1 activity this would seem to be consistent with these observations. Overall, these data support the proapoptotic, tumor-suppressing effects of IRF-1 in multiple cancer cell types (Tanaka and Taniguchi, 2000) .
The proapoptotic capacity of IRF-1 expression may contribute to its known role as a tumor suppressor gene (Tanaka et al., 1994a) . IRF-1 À/À embryonic fibroblasts can become transformed by introduction of just one oncogene, c-Ha-ras. This is significant because transformation of wild-type embryonic fibroblasts usually requires at least two oncogenes. Moreover, NIH3T3 cells transformed by two other oncogenes (c-myc and fosB) could also be reverted to their normal phenotype by ectopic expression of IRF-1 (Tanaka et al., 1994b) . This is significant because while these cells were minimally transformed by the addition of only one oncogene, IRF-1 was able to suppress these unrelated oncogenes as opposed to replacing the same deficient tumor suppressor.
Notably, Ad-IRF-1 did not suppress growth or induce apoptosis in C127I or NMuMG nontransformed mammary epithelial cells (Figure 3d) . One mechanism for this would include the phenomenon where activation of the oncogene HER1 was required to induce apoptosis by IRF-1 expression in nonmalignant NIH3T3 cells (Kirchhoff and Hauser, 1999) . Interestingly, Chapman et al. (2000) demonstrated that IRF-1 can have an antiapoptotic role in nontransformed mammary epithelial cells during mammary gland involution. In evaluating the mammary glands of IRF-1 À/À mice, significantly higher numbers of apoptotic cells were found in involuting glands in the absence of IRF-1. In addition, the alveolar structure had collapsed when compared to control wild-type IRF-1 mouse glands. This is the only study to demonstrate an antiapoptotic role for IRF-1, and confirms the possibility that IRF-1 may produce different results in nontransformed mammary epithelial cells compared to malignant breast cells.
While apoptosis appears to play a role in the tumor suppression demonstrated in vitro and in vivo in our studies, there certainly may be other mechanisms for the antitumor effect, particularly in vivo. Since intratumoral delivery of recombinant adenovirus cannot allow for transduction and overexpression of IRF-1 into every cancer cell, the fact that significant tumor suppression was seen in vivo may be due to a significant paracrine effect from soluble factors like cytokines such as IFN-a. However, soluble factors do not appear to be the primary mechanism for growth inhibition in vitro, because we have not found significant inhibition of growth from treatment of breast cancer cells with the media from Ad-IRF-1-infected cells (data not shown). IFN-a is known to have a growth-suppressive effect in vitro and in vivo, and is used clinically in the treatment of melanoma (Kirkwood et al., 2001) ; this cytokine may have an antitumor effect in cells not transduced with Ad-IRF-1. However, even though NMuMG cells expressed high levels of IFN-a in response to Ad-IRF-1 (Figure 1c) , the cell growth of NMuMG cells was not affected (Figure 3d) , and apoptosis was not induced in these cells (data not shown). Therefore, it is unlikely that the growth-suppressive effects in C3-L5 and TS/A carcinomas are mediated solely by IFN-a.
Nitric oxide is another soluble factor that could play a role in the cell death induced by IRF-1. Nitric oxide has proapoptotic or antiapoptotic effects depending on local concentrations and cell type (Kim et al., 2001) . IRF-1 overexpression also induced iNOS expression and nitric oxide production in C3-L5 cells (data not shown). However, iNOS expression alone by Ad-iNOS infection with nitric oxide production did not induce apoptosis in C3-L5 cells (data not shown). The lack of a role for iNOS and nitric oxide in breast cell inhibition was confirmed by using the inhibitors l-N G -monomethyl-larginine (l-NMA) and l-N 6 -(1-iminoethyl)lysine (l-NIL). Coincubation of Ad-infected cells with l-NMA or l-NIL completely suppressed nitrite production but did not alter the effects of Ad-IRF-1 on growth inhibition (data not shown). Moreover, despite inducing apoptosis in TS/A cells (Figure 2b ), Ad-IRF-1 did not appear to upregulate iNOS in TS/A breast cancer cells and did not generate nitrite production in this cell line (data not shown). These results suggest that iNOS expression and production of nitric oxide were not directly involved in cell death induced by IRF-1 expression in C3-L5 or TS/A cells. However, this does not exclude the possibility that nitric oxide has a paracrine effect on nontumor cells in the C3-L5 model in vivo. Finally, we cannot exclude enhanced immunity to injected tumors in vivo either by upregulation of MHC class I and II proteins or other cell surface or soluble proteins that may enhance an immune response, and this requires further study. We do believe that these data demonstrate a very significant role for apoptosis in the antitumor effect seen with IRF-1 upregulation in breast cancer cells.
We believe our studies demonstrating the induction of apoptosis by IRF-1 in breast cancer cells improves the understanding of the mechanisms of signal transduction of cytokines, and this step is critical to the evaluation of these agents in the treatment of cancer. Our results support attempts to increase IRF-1 activity in the treatment of breast cancer, and future studies will be designed to determine the mechanisms and necessary targets of IRF-1 that influence the induction of tumorspecific apoptosis in breast cancer cells.
Materials and methods
Materials and cell lines
C3-L5 (Brodt et al., 1985) and TS/A (Nanni et al., 1983) murine adenocarcinoma cell lines were obtained and cultured in RPMI-1640 (Bio-Whittaker; Walkersville, MD, USA) with 10% fetal calf serum and antibiotics. Caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp fluoromethylketone (Z-VAD-fmk) was obtained from Alexis Corp (San Diego, CA, USA). Stock solution of Z-VAD was prepared at 100 mm in dimethylsulfoxide (DMSO). Antibodies used for this study were purchased from Sigma (St Louis, MO, USA for b-Actin), and Santa Cruz (caspase-3, caspase-7, and IRF-1; Santa Cruz, CA, USA). BCA Protein and Supersignalt chemiluminescence detection reagents were obtained from Pierce (Rockford, IL, USA). Unless otherwise indicated, all other reagents were purchased from Sigma (St Louis, MO, USA).
Immunoblotting analysis
A total of 40 mg of protein were separated by SDS-PAGE and transferred onto a nitrocellulose membrane. Loading of equal protein amounts was assessed by staining of nitrocellulose membranes with 0.1% Ponceau S (Sigma) in 5% acetic acid. Nonspecific binding was blocked with PBS-T (14 mm sodium phosphate, monobasic, monohydrate; 88 mm dibasic sodium phosphate, anhydrous; 100 mm NaCl; and 0.1% Tween 20) containing 5% nonfat milk for 1-h incubation with agitation at room temperature. Anti-IRF-1 (1 : 1000), caspase-3 (1 : 1000), caspase-1 (1 : 500), caspase-7 (1 : 1000), or anti-b-actin (1 : 1000) antibodies were added. After 1-h incubation at room temperature with agitation, membranes were washed three times with PBS-T. The appropriate horseradish peroxidaseconjugated goat anti-rabbit secondary antibody (Amersham Pharmacia Biotech, Piscataway, NJ, USA) was incubated at 1 : 10 000 for 1 h at room temperature. Following five washes with PBS-T, the protein bands were visualized with Supersignalt (Pierce) according to the manufacturer's instructions. The bands were visualized on Kodak film (Eastman Kodak, Rochester, NY, USA) exposed to the membrane to detect chemiluminescence signals.
Viral vectors and infection
E1-and E3-deleted Ad-IRF-1 was constructed through Crelox recombination as described by Dr S Hardy (Somatix, Alameda, CA, USA). The mouse IRF-1 gene was inserted into the shuttle vector pAdlox to create Ad-IRF-1. Recombinant Ad-IRF-1 was generated by cotransfection of Sfi I-digested pAdlox-mIRF-1 and Psi5 helper virus DNA into the Ad packaging cell line CRE8 that expressed Cre recombinase as previously described (Hardy et al., 1997) . Recombinant adenoviruses were propagated on CRE8 or 293 cells and purified by cesium chloride density gradient centrifugation and subsequent dialysis. Titers of viral particles were determined by optical densitometry using a validate assay (SOP QC100-A), and recombinant viruses were stored in 3% sucrose at À801C. The presence of the viral transgene product IRF-1 was confirmed by Western blot analysis of infected breast cancer cells. PFU were estimated at 100 particles per PFU. Adenovirus that expresses enhanced green fluorescent protein (Ad-EGFP) was obtained (Takahashi et al., 2000) , and Ad-C5 was a gift from S Hardy.
For adenoviral transduction of cells, recombinant adenovirus was added to cultures at increasing MOIs in serum-free Opti-MEM. Cells were incubated for 4 h at 371C and 5% CO 2 . Following this, cells were washed twice with PBS and fresh media containing 10% calf serum was added. Cell cultures were infected with increasing MOI of control Ad-EGFP, and the efficiency of gene transfer was assessed by fluorescent microscopy.
Cell growth assay
C3-L5, TS/A, C127I, and NMuMG cells were infected at MOIs 200, 200, 200 , and 25, respectively, for 4 h with Ad-IRF-1, Ad-C5, and mock (no virus). After 24 h, 100 ml methylthiazoltetrazolium (MTT; 0.5 mg/ml) was added per well to the existing 1 ml media and incubated for 3 h. Supernatant was removed and cells were dried overnight at room temperature. DMSO (200 ml) was added per well and OD measurements were taken in 96-well plates by UV spectrophotometry at 550 nm. Cell viability was calculated from relative dye intensity of the mean for duplicate samples and presented as percentages relative to untreated samples.
Apoptosis assay and flow cytometry
Apoptosis was assessed by flow cytometric analysis of cells stained with Annexin V-FITC and PI using a Becton Dickinson FACSortt (San Jose, CA, USA). Cells were harvested using 0.05% trypsin, rinsed in PBS, and suspended in 100 ml annexin-binding buffer (10 mm HEPES/NaOH, pH 7.4; 140 mm NaCl; 2.5 mm CaCl 2 ), 5 ml/100 ml of Annexin V-FITC, and 5 mg/ml of PI (BD PharMingen, San Diego, CA, USA). Emission filters used were bandpass 530/30 nm (FITC) and bandpass 585/42 nm (PI). A minimum of 10 000 cells per sample was recorded, and cell debris was excluded by appropriate forward light scatter threshold setting. Data analysis using CELLQuestt software (Becton Dickinson, St Louis, USA) was performed, and numbers of cells positive for Annexin V-FITC, PI, or combinations thereof, were calculated.
Caspase-3 activity assay
Cells treated with Ad-IRF-1 or Ad-C5 were harvested by scraping, and cell pellets were resuspended in 1 Â CHAPS cell lysis buffer (Cell Signaling Technologies) containing 2 mm dithiothreitol and 1 mm PMSF. The cell suspension was lysed by four freeze-thaw cycles and the cytosolic fraction obtained by centrifugation at 12 000 g for 15 min at 41C. Caspase-3 Activity was determined using the CaspACE Fluorometric Assay System (Promega, Inc.) as per the manufacturer's instructions. Briefly, protein extracts were incubated with caspase-3 fluorogenic substrate (Ac-DEVD-AMC; 50 mm), with or without caspase-3 inhibitor (Ac-DEVD-CHO; 50 mm), at 371C for 1 h. The increase in fluorescence of enzymatically released AMC was measured on a SpectraMax GeminiXS fluorescence detector (Molecular Devices) with an excitation wavelength of 360 nm and an emission wavelength of 460 nm. Proteolytic cleavage of AMC was determined by calibration with known AMC standards. Caspase-3 activity was determined by the difference in cleavage rates of samples incubated with and without caspase-3 inhibitor.
Animal studies
All procedures in this experiment were performed according to the guidelines of the Council on Animal Care at the University of Pittsburgh and the National Research Council's Guide for the Care and Use of Laboratory Animals.
In vivo tumor growth of C3-L5 and TS/A cells preinfected or intratumorally injected with Ad-IRF-1 C3-L5 or TS/A cells were transfected ex vivo with Ad-IRF-1 (n ¼ 5, MOI 200), Ad-C5 (n ¼ 5, MOI 200), or mock (no virus, n ¼ 10) for 4 h. C3-L5 cells (5 Â 10 5 ) (10 5 for TS/A cells) were then injected into 7-9-week-old female C3H/HeJ (BALB/c for TS/A cells) syngeneic mice subcutaneously in the mammary line. For intratumoral injections of tumors, uninfected C3-L5 or TS/A cells were similarly injected subcutaneously into C3H/ HeJ or BALB/c mice, respectively. When tumors had grown to 3.5-4.5 mm in diameter, animals were randomized and injected intratumorally with 2 Â 10 8 PFU Ad-IRF-1 or Ad-C5 (n ¼ 5 per group) in 0.1 ml Hank's buffered salt solution. Tumors were measured three times weekly by serial measurements of perpendicular diameters using calipers. Animals that were moribund or reached greater than 400 mm 2 in area were killed.
Microarray analysis by Affymetrix chip hybridization
For cRNA preparation, total RNA was extracted and purified with Qiagen RNeasy kit (Qiagen, San Diego, CA, USA). Total RNA (5 mg) was used in the first strand cDNA synthesis with T7-d(T) 24 primer (GGCCAGTGAATTGTAATACGACT-CACTATAGGGAGGCGG-(dT) 24 ) by Superscriptt II (GIB-CO-BRL, Rockville, MD, USA). The second strand cDNA synthesis was carried out at 161C by adding E. coli DNA ligase, E. coli DNA polymerase I, and RnaseH in the reaction. This was followed by the addition of T4 DNA polymerase to blunt the ends of newly synthesized cDNA. The cDNA was purified through phenol/chloroform and ethanol precipitation. The purified cDNA was then incubated at 371C for 4 h in an in vitro transcription reaction to produce cDNA labeled with biotin using MEGAscriptt system (Ambion, Inc., Austin, TX, USA). A total of 15-20 mg of cDNA were fragmented by incubating in a buffer containing 200 mm Tris-acetate, pH 8.1, 500 mm KOAc, 150 mm MgOAc at 951C for 35 min. The fragmented cDNA was then hybridized with a pre-equilibrated Affymetrix chip at 451C for 14-16 h. After the hybridization cocktails were removed, the chips were then washed in a fluidic station with low-stringency buffer (6 Â SSPE, 0.01% Tween 20, 0.005% antifoam) for 10 cycles (two mixes/cycle) and stringent buffer (100 mm MES, 0.1 m NaCl, and 0.01% Tween 20) for four cycles (15 mixes/cycle), and stained with SAPE (Strepto-avidin Phycoerythrin). This was followed by incubation with biotinylated mouse anti-avidin antibody, and restained with SAPE. The chips were scanned in an HP ChipScanner (Affymetrix Inc., Santa Clara, CA, USA) to detect hybridization signals. The P-value was derived from a paired t-test (16 pairs) between the control samples (mock-or Ad-C5-infected) and TS/A cells infected with Ad-IRF-1.
Northern blotting
Total RNA from cells transfected with 200 MOI Ad-C5 or Ad-IRF-1 or mock was extracted with 0.2 ml/10 6 cells RNAzol at 2, 4, 8, 12, 18 , and 24 h. RNA was purified through isopropanol and 75% ethanol washes. A total of 20 mg of denatured RNA samples were electrophoresed with Bromophenol blue in a 1% agarose/1% formaldehyde gel. RNA was transferred onto a Gene Screen membrane (NEN Life Science, Boston) overnight. Blots were prehybridized for 2 h with salmon sperm DNA and then hybridized overnight at 451C [a-32 P]dCTP-labeled probes for Bak (R&D Systems, Minneappolis), or caspase-8. Blots were washed with 2 Â SSC buffer with 0.1% SDS, twice with 0.04% SDS, then 0.01 m EDTA at 531C, and exposed to a phosphoimager. To confirm equal loading of Northern blots, 18S mRNA was photographed while being exposed to UV light.
Statistical analyses
Data are presented as means7standard error of the mean or standard deviation with representative experiments of multiple experiments depicted in each figure. Comparisons between values were analysed using analysis of variance (ANOVA) or ttest. Differences were considered significant at P-values p0.05. Tumor-free survival was analysed statistically by Fisher's twosided exact test.
